AMAG Share Price

Open 23.95 Change Price %
High 24.20 1 Day -0.15 -0.63
Low 23.28 1 Week -0.40 -1.66
Close 23.75 1 Month -0.25 -1.04
Volume 927368 1 Year -2.79 -10.51
52 Week High 36.83
52 Week Low 17.92
AMAG Important Levels
Resistance 2 24.60
Resistance 1 24.25
Pivot 23.74
Support 1 23.25
Support 2 22.90
NASDAQ USA Most Active Stocks
NVDA 100.49 -9.27%
JBHT 97.31 -1.05%
AREX 2.96 -1.99%
OZRK 55.54 1.02%
FNSR 34.15 0.12%
AGNC 19.64 0.72%
EA 86.65 -0.84%
FNFG 10.18 -0.20%
PRFZ 118.04 -0.80%
DELL 13.86 0.22%
NASDAQ USA Top Gainers Stocks
ECTE 0.18 50.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
ZAZA 0.06 20.00%
JAKK 5.70 12.87%
LINE 0.18 12.50%
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)

AMAG Technical Analysis 4
As on 23rd Feb 2017 AMAG Share Price closed @ 23.75 and we RECOMMEND Sell for LONG-TERM with Stoploss of 25.61 & Strong Sell for SHORT-TERM with Stoploss of 28.16 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMAG Target for February
1st Target up-side 32.41
2nd Target up-side 38.24
3rd Target up-side 44.06
1st Target down-side 15.79
2nd Target down-side 9.96
3rd Target down-side 4.14
AMAG Other Details
Segment EQ
Market Capital 334970336.00
Sector Healthcare
Industry Diagnostic Substances
Offical website
AMAG Address
1100 Winter Street
Waltham, MA 02451
United States
Phone: 617-498-3300
Fax: 617-499-3361
Interactive Technical Analysis Chart AMAG Pharmaceuticals, Inc. ( AMAG NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on AMAG Pharmaceuticals, Inc.
AMAG Business Profile
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The Company markets and sells Feraheme in the United States through its own commercial organization. Feraheme is approved for use in the treatment of both dialysis and non-dialysis dependent chronic kidney disease (CKD) patients. The Company’s principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). In December 2011, Feraheme was also granted marketing approval in Canada for use as an IV iron replacement therapy for the treatment of IDA in adult patients with CKD. GastroMARK, which is marketed and sold under the trade name Lumirem outside of the United States, is the Company’s oral contrast agent used for delineating the bowel in magnetic resonance imaging (MRI), and is approved and marketed in the United States, Europe, and other countries through its licensees. The Company markets and sells Feraheme in both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD. There are two methods used to treat IDA in CKD patients: oral iron supplements and IV iron. Oral iron supplements are often not absorbed well by the gastrointestinal tract and frequently have unpleasant side effects, such as constipation, diarrhea, and cramping, which can cause patients to stop taking their medication. In addition, it can take an extended time for hemoglobin levels to improve the initiation of oral iron treatment.